The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Suspect they can submit for ODD for multiple new targets (beyond STS)
Additionally, Avacta now undoubtedly has sufficient data to achieve FDA Fast track support. They didn't inform the market when ODD was submitted so I expect we will hear further upon FDA approval
Ronny
If CDO/CSO were partly responsible for the bad advice leading to the last min placing, I can see why they departed.
I've been scratching my head on this one but this theory could make sense.
My take...
There was a LD under discussion to support phase 2 funding. For whatever reason this deal has dragged on leading Avacta to opt for the placing option.
As has been said, we are now not reliant on LD funds and can negotiate much more strongly.
Aa CEO said, we now move forward at speed
The discounted placing is obviously bad however, the cash in the bank strengthens our position considerably.
Avacta sanctioned the CBO position as they felt it was possible to leverage the clinical data/progress and commercialize the platform. Why recruit the CBO if there was no interested parties? The cash in the bank will ensure we have a strong position when negotiating on the licensing terms.
While it may not feel good today, we do have lots to look forward to during the coming weeks/months and im sure the share price will recover quickly:
License deals
AACR data release
Ava6k progress
US listing
Dx sales / cash injection
Affyxell update
There was a huge amount of money on the sidelines pending this finance update, which I am sure will now flow back.
AS will be under huge pressure now so he will need to urgently pump the share price.....
Agree - the tech is blockbuster and I can only see positive news incoming. Would very much welcome a strong II to ensure we are able to see the maximum value
Hey Stevo,
Any analysis on decom liabilities ?
§ Net debt c. $481 million at 31 December 2023; a c. $236 million reduction versus 31 December 2022.
Enq can be debt free by end of 2025 (assuming no more debt via m&a).
The share price will react soon.
This is a great buy (r vs r) opportunity regardless of Labour risk and I'm happy to be massively overweight.
Switch off and come back in 6 months. I think we could easily be double or treble of 13p.
I'm sure he would be buying more at current value if he could.
I suspect he cannot as M&A deals are likely under discussion.
'§ c. $500 million liquidity at 31 December 2023, providing a platform for transformational transactional growth, enhanced by EnQuest's advantaged UK tax position'
Enq 12p!!
Massive disconnect
Great news!